AbbVie prices $10B multi-tranche senior notes offering to fund Apogee acquisition

AbbVie Inc.

Issued $10B aggregate principal across 9 tranches: floating rate notes due 2028, fixed-rate notes from 2028 to 2066 with coupons 4.500% to 6.100%.
Net proceeds ~$9.93B; closing expected August 18, 2026.
Proceeds to partially fund AbbVie's cash payment obligations for Apogee acquisition and for general corporate purposes, including debt repayment.
The offering reduces commitments under AbbVie's $10B 364-day delayed draw term loan facility related to the Apogee acquisition.
Underwriters include Morgan Stanley, BofA Securities, J.P. Morgan, SG Americas Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.